Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…Abstract Number: 0814 • ACR Convergence 2025
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…Abstract Number: 0481 • ACR Convergence 2025
Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
Background/Purpose: Methotrexate (MTX) polyglutamates (MTX-PGs), the intracellular active forms of MTX, are hypothesized to reflect cumulative exposure and potentially predict therapeutic efficacy in rheumatoid arthritis…Abstract Number: 0465 • ACR Convergence 2025
Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with…Abstract Number: 0448 • ACR Convergence 2025
Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Background/Purpose: Although Large Language Models (LLMs) have been successfully used in the analysis of data from Electronic Health Records (EHRs), their implementation in the field…Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…Abstract Number: 0221 • ACR Convergence 2025
A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-Centered National Rheumatoid Arthritis Network
Background/Purpose: Clinical guidelines recommend the use of disease activity measures (DAMs) in rheumatoid arthritis (RA) management. Measurement of DAMs is also a critical component of…Abstract Number: 0166 • ACR Convergence 2025
Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
Background/Purpose: Environmental influences affect the human body throughout life, from conception to old age. The influence of air pollution and fine dust particles on systemic…Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…Abstract Number: 0067 • ACR Convergence 2025
Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
Background/Purpose: Symptomatic rheumatoid arthritis-related interstitial lung disease (RA-ILD) is prevalent in about 10% of patients with RA and confers a higher mortality compared with RA…Abstract Number: 0022 • ACR Convergence 2025
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…Abstract Number: 2641 • ACR Convergence 2025
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…Abstract Number: 2275 • ACR Convergence 2025
Agreement Between Two Rheumatoid Arthritis Response Measures Across b/ts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood-based Precision Medicine Test
Background/Purpose: Contemporary pharmacological management of rheumatoid arthritis (RA) is set within a treat-to-target framework. This requires quantitative, longitudinal assessments of disease activity with a view…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 219
- Next Page »
